Related Experiment Video
Updated: Jul 10, 2026
08:04
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
Managing herpes zoster in immunocompromised patients
Ammar M Ahmed1, Julie S Brantley, Vandana Madkan
1Baylor College of Medicine, Houston, TX, USA.
Herpes : the Journal of the IHMF
|October 18, 2007
Summary
Prompt antiviral therapy is crucial for immunocompromised patients with herpes zoster (shingles) to prevent complications. Early treatment with oral or intravenous antivirals, alongside pain management, improves outcomes and reduces disease severity.
Area of Science:
- Infectious Diseases
- Immunology
- Dermatology
Background:
- Herpes zoster (shingles) poses significant risks for immunocompromised individuals.
- Complications include cutaneous and visceral dissemination, potentially life-threatening.
- Effective management aims to prevent disease spread and severe outcomes.
Purpose of the Study:
- To outline optimal management strategies for herpes zoster in immunocompromised patients.
- To emphasize the importance of timely antiviral intervention.
- To guide treatment decisions based on disease severity and patient status.
Main Methods:
- Review of clinical guidelines and evidence for herpes zoster management.
- Focus on antiviral therapy timing and route of administration.
- Consideration of pain management and specific drug choices.
Main Results:
- Prompt antiviral therapy, initiated within one week of rash onset or before crusting, is key.
- Oral antivirals (valaciclovir, famciclovir, aciclovir) are suitable for localized disease.
- Intravenous aciclovir is reserved for severe cases, disseminated infection, or oral intolerance.
- Foscarnet is indicated for aciclovir-resistant infections.
- Analgesic therapy is essential for acute and post-herpetic neuralgia.
Conclusions:
- Early antiviral treatment is critical for managing herpes zoster in immunocompromised patients.
- Tailoring therapy based on disease presentation and patient factors ensures optimal outcomes.
- Integrated antiviral and analgesic strategies reduce morbidity.
Related Concept Videos
01:20Chickenpox
Chickenpox is an acute, highly contagious disease caused by the varicella-zoster virus (VZV), a double-stranded DNA virus belonging to the Herpesviridae family. Its transmission occurs primarily through the inhalation of respiratory droplets or direct contact with vesicular fluid from skin lesions. The incubation period typically ranges from 10 to 21 days, during which the virus replicates and disseminates through sequential phases within the host. Although generally self-limiting in children,...
01:23Genital Herpes
Genital herpes is a sexually transmitted infection primarily caused by herpes simplex virus type 2 (HSV-2), though herpes simplex virus type 1 (HSV-1) is increasingly implicated in genital infections, particularly among younger populations. Transmission occurs mainly through sexual contact, with asymptomatic viral shedding serving as a major route of spread. This characteristic makes HSV-2 difficult to control at a population level, as individuals may unknowingly transmit the virus even in the...
01:28Herpes
Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
01:24Smallpox
Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...